Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Iyer A
Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,
Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,
Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Vandamme T
Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,
Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,
Introduction: 8-20% of patients with VHLD develop PNETs. However, there are no markers for PNETs progression in VHLD patients. The type of mutation in VHL gene is associated with clinical phenotype of VHLD.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Tirosh A
Authors: Tirosh A, Shell J, Keutgen X, Sadowski S, Green P,
Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Lupp A
Authors: Mai R, Kaemmerer D, Sänger J, Neubauer E, Schulz S,
Keywords: somatostatin receptor, CXCR4,
Introduction: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Kaemmerer D
Authors: Kaemmerer D, Sänger J, Arsenic R, D'Haese J, Neumann J,
Keywords: paraganglioma, somatostatin, CXCR4,